According to a recent KPMG report, the global M&A landscape in 2024 signals a rebound despite challenges like geopolitical tensions, high ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...

ALS is a progressive neurodegenerative disease that currently has no cure. Commonly known as Lou Gehrig’s disease, ALS ...

Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...

Black & Veatch (Overland Park, Kan.) has been selected by two U.K.-based companies as the Owner’s Engineer (OE) and Technical ...

– Initiating Phase 2 trial to evaluate lorundrostat for the treatment of patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension – ...

Farallon presses Astellas to cut costs and overhaul drugs research in latest shareholder campaign gripping Tokyo ...

M&A markets don't like volatility and unpredictability, and what we've seen in the past few weeks is the opposite of that,” ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Mitsubishi Chemical Group Corp. (MCG; Tokyo) announced that it has decided to transfer its consolidated subsidiary Mitsubishi Tanabe Pharma Corp. (MTPC; ...

Bain's latest acquisition follows a string of hefty investments the private equity firm has made in Japan in recent months.